segunda-feira, outubro 23, 2006
Cancro, ciência e marketing
Integrity in Science Watch - October 23, 2006
The Integrity in Science Database of Scientists and Organizations With Ties to Industry can be found at: www.integrityinscience.org.
Cancer Groups Withdraw from Campaign Funded Solely by Drug Firm
The representatives of two European anti-cancer advocacy groups have pulled out from a major initiative funded entirely by one of the world's largest makers of anti-cancer drugs. Adamos Adamou, a Member of the European Parliament (MEP) who withdrew from the Cancer United board after attending one meeting, wrote a letter with two to other MEPs to the chair of the board, citing their concern "about the transparency of the...initiative." The chairman of the European Cancer Patients Coalition also asked to be removed from the board after she was listed as a member without her consent. Roche, a leading manufacturer of breast and lung cancer drugs, launched the Cancer United initiative last week in Brussels to bring together "all parties concerned with the care of all cancer patients...in Europe."
Meanwhile, top oncologists have criticized the Roche-funded study on which the initiative is based, which was conducted by the Karolinska Institute in Stockholm. That study linked patient survival to the amount governments spend on cancer drugs. Due to this initiative, "governments will no doubt be pressed to fund a big increase in expenditure on cancer drugs - on the entirely spurious grounds that such an increase has been proven to increase national survival rates," said Michel Coleman from the London School of Hygiene and Tropical Medicine.
The Integrity in Science Database of Scientists and Organizations With Ties to Industry can be found at: www.integrityinscience.org.
Cancer Groups Withdraw from Campaign Funded Solely by Drug Firm
The representatives of two European anti-cancer advocacy groups have pulled out from a major initiative funded entirely by one of the world's largest makers of anti-cancer drugs. Adamos Adamou, a Member of the European Parliament (MEP) who withdrew from the Cancer United board after attending one meeting, wrote a letter with two to other MEPs to the chair of the board, citing their concern "about the transparency of the...initiative." The chairman of the European Cancer Patients Coalition also asked to be removed from the board after she was listed as a member without her consent. Roche, a leading manufacturer of breast and lung cancer drugs, launched the Cancer United initiative last week in Brussels to bring together "all parties concerned with the care of all cancer patients...in Europe."
Meanwhile, top oncologists have criticized the Roche-funded study on which the initiative is based, which was conducted by the Karolinska Institute in Stockholm. That study linked patient survival to the amount governments spend on cancer drugs. Due to this initiative, "governments will no doubt be pressed to fund a big increase in expenditure on cancer drugs - on the entirely spurious grounds that such an increase has been proven to increase national survival rates," said Michel Coleman from the London School of Hygiene and Tropical Medicine.
